Monsanto: Anderson must uproot Bayer’s perennial problem - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

Monsanto: Anderson must uproot Bayer’s perennial problem

New chief needs to signal to investors whether a restructuring is likely

Bayer’s 2018 acquisition of US crop science company Monsanto is the takeover that just keeps on taking. This week’s €2.5bn impairment charge adds to already extensive financial damage. It will reinvigorate activist demands for a break-up.

Bayer paid $65bn for Monsanto assets that included a glyphosate weedkiller called Roundup. Management initially underestimated the high cost of an accompanying health scare, as managements typically do. Allegations that Roundup is carcinogenic have prompted numerous lawsuits.

Bayer trades at a depressed enterprise valuation of about 7 times forward ebitda. Change may now be in the air. Werner Baumann, the chief executive responsible for the Monsanto purchase, has stepped aside after a long period of poor share price performance. Replacement Bill Anderson started last month. As a former Roche executive, his expertise is drugs, not weedkillers.

A couple of things look odd about the impairment. First, it is relatively small, given that Bayer has about €39bn of goodwill on its balance sheet, more than half of which derives from the Monsanto acquisition. Second, Bayer blames a weak glyphosate market, which might be a temporary phenomenon, for the writedown. About 60 per cent of world sales are generic products, most of which are made in China.

Anderson will hopefully substitute signal for noise when he presents earnings on August 8. He should signal whether a restructuring is likely. Activists Inclusive Capital and Bluebell have called for this. They favour a spinout of the crop science unit, a business that troubles environmental, social and governance investors.

That would make sense. Even at 10 times next year’s ebitda, a sixth cheaper than rivals FMC and Corteva, Bayer’s crop science unit should be worth about €60bn, 2024 Visible Alpha estimates imply — albeit undiscounted for a long tail of legal claims. Compare that with the group’s total enterprise value of €86bn.

Bayer has argued that cash flow from crop science and its consumer health unit help fund its growing pharmaceuticals pipeline. But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change.

Anderson wishes to boost pharma, for example, by removing centralised research budgeting. But that could take years to lift the group’s low valuation. Like all incoming bosses, he has a brief window to cut loose a problem division. He should exploit it.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

美伊开战,特朗普将其总统职位作为赌注

美国总统在数月前曾誓言让美国远离新的冲突,如今却加入了以色列对德黑兰的攻击。

Alexandr Wang的崛起:Meta对Scale AI的28岁CEO的140亿美元押注

Meta首席执行官马克•扎克伯格斥巨资聘请人脉广泛的企业家,以重振公司的人工智能雄心。

Pimco在“混乱”市场中押注日本长期债务

长期借款成本飙升至历史新高,债券投资巨头买入。

美国轰炸伊朗核基地

轰炸机袭击福尔道、纳坦兹和伊斯法罕后,特朗普要求德黑兰寻求和平,否则将面临更多袭击。

AI怀疑者艾米丽•本德:‘皇帝没有穿衣服’

这位计算语言学家谈及她为何要挑战大型科技公司、聊天机器人带来的风险——以及为什么人工智能不过是“升级版的魔法8球”。

特朗普在攻击伊朗后面临Maga基本盘的强烈反对

批评人士担心,美国军方人员可能会遭到伊朗及其代理人的报复。
设置字号×
最小
较小
默认
较大
最大
分享×